Added to YB: 2026-02-10
Pitch date: 2026-02-06
RGNX [neutral]
REGENXBIO Inc.
-17.06%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Market Cap
$522.9M
Pitch Price
$10.14
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.90
P/E
-2.98
EV/Sales
3.03
Sector
Biotechnology
Category
special_situation
Biotech Catalysts on My Radar | February 2026 - REGENXBIO Inc.
RGNX (quick overview): Gene therapy for Hunter syndrome w/ Feb 8 PDUFA date uncertain after FDA clinical hold due to CNS tumor in related RGX-111 study. RGX-121 shows strong efficacy in 30+ patients, no similar events reported. Hold based on shared vector platform. Positive outcome clears path to approval in high unmet need indication.
Read full article (2 min)